Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 433-438

  Blondeau, J M ^a   Zhao, X ^a   Hansen, G ^a   Drlica, K ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; DOSE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; DNA, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMOCOCCAL INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0035139520     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.433-438.2001     Document Type: Article

References (29)

1. Bacterial counts in cerebrospinal fluid of children with meningitis
2. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
3. A review of clinical trials with fluoroquinolones with an emphasis on new agents
4. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
5. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
6. Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis
7. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonus sepsis
8. Pharmacokinetics of grepafloxacin
9. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis
10. Primary targets of fluoroquinolones in Streptococcus pneumoniae
11. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
12. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
13. Multidrug resistance - A sign of the times
14. Development of resistance during antibiotic therapy
15. Drug resistance in mycobacteria
16. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistant phenotype
17. Mechanisms of quinolone resistance
18. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
19. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
20. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
21. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
22. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
23. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
24. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
25. The epidemiology of bacterial resistance to antimicrobial agents
26. Pharmacokinetics and pharmacodynamics of fluoroquinolones
27. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies
28. DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance